Epileptic encephalopathies of infancy: welcome advances

@article{Berkovic2020EpilepticEO,
  title={Epileptic encephalopathies of infancy: welcome advances},
  author={Samuel F. Berkovic},
  journal={The Lancet},
  year={2020},
  volume={394},
  pages={2203-2204}
}
  • S. Berkovic
  • Published 13 December 2019
  • Medicine
  • The Lancet

Topics from this paper

References

SHOWING 1-10 OF 11 REFERENCES
Stiripentol for the treatment of seizures associated with Dravet syndrome
  • C. Chiron
  • Medicine
    Expert review of neurotherapeutics
  • 2019
TLDR
Stiripentol could be especially useful in two critical conditions of the disease, very young age (<2 years) and convulsive status epilepticus, and seizure freedom seems occasionally be obtained with fenfluramine.
A population‐based cost‐effectiveness study of early genetic testing in severe epilepsies of infancy
TLDR
This study sought to determine the incidence and etiologies of SEI, and model the yield and cost‐effectiveness of early genetic testing.
Nusinersen versus Sham Control in Infantile‐Onset Spinal Muscular Atrophy
TLDR
Those who received nusinersen were more likely to be alive and have improvements in motor function than those in the control group and infants with a shorter disease duration at screening wereMore likely than those with a longer disease duration to benefit from nusineren.
Trial of Cannabidiol for Drug‐Resistant Seizures in the Dravet Syndrome
TLDR
Among patients with the Dravet syndrome, cannabidiol resulted in a greater reduction in convulsive‐seizure frequency than placebo and was associated with higher rates of adverse events.
Mortality in Dravet syndrome
Low-dose fenfluramine in the treatment of neurologic disorders: experience in Dravet syndrome
TLDR
A prospective study of patients with Dravet syndrome treated with low-dose fenfluramine and the initial results are promising in terms of reduction of seizure frequency and overall tolerability.
Successful use of fenfluramine as an add‐on treatment for Dravet syndrome
TLDR
Examination of the potential anticonvulsive effects of fenfluramine in a clinical trial consisting of a small group of patients diagnosed with Dravet syndrome is permitted.
Severe myoclonic epilepsy in infancy (Dravet syndrome) 30 years later
TLDR
Dravet syndrome is considered as an ‘‘epileptic encephalopathy’’ defined as a condition in which the epileptiform abnormalities themselves are believed to contribute to the progressive disturbance in cerebral function, however, it is not proven that the cognitive decline observed in the first stages of the disease is simply the direct consequence of epilepsy.
...
1
2
...